Verastem Oncology to Announce Fourth Quarter and Full-Year 2018 Financial Results and Corporate Update on March 12, 2019

On February 26, 2019 Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, reported that the Company will host a conference call and webcast on Tuesday, March 12, 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and year ended December 31, 2018 (Press release, Verastem, FEB 26, 2019, View Source;p=irol-newsArticle&ID=2388942 [SID1234533686]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The call can be accessed by dialing (877) 341-5660 (U.S. and Canada) or (315) 625-3226 (international), five minutes prior to the start of the call and providing the passcode 2849017. The live, listen-only webcast of the conference call can be accessed by visiting the investors section of the Company’s website at www.verastem.com. A replay of the webcast will be archived on the Company’s website for 90 days following the call.

Immutep to Present at Upcoming Industry Conferences

On February 26, 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, reported its participation in various upcoming industry conferences (Press release, Immutep, FEB 26, 2019, View Source [SID1234533730]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company will be presenting updated clinical data from the Phase I TACTI-mel trial in metastatic melanoma for its lead product candidate eftilagimod alpha ("efti" or "IMP321") and new data relating to its pre-clinical product candidate, IMP761, a novel anti-LAG-3 agonist antibody for the treatment of auto-immune diseases, at industry conferences in March 2019.

Conference:

World Immunotherapy Congress USA 2019

Dates:

3-5 March 2019

Venue:

Grand Hyatt, San Diego, USA

Presentation Title:

Two ACTive Immunotherapies (TACTI): Results of a Phase I trial with metastatic melanoma patients

Presenter:

Dr. Frédéric Triebel, CSO and CMO of Immutep

Conference:

14th Congress of ECCO (European Crohn’s and Colitis Organisation)

Dates:

6-9 March 2019

Venue:

Bella Center, Copenhagen, Denmark

Presentation Title:

IMP761, a novel anti-LAG-3 agonist antibody for the treatment of auto-immune diseases

Presenter:

Mathieu Angin, Phd, Immutep Research Scientist

Omeros Corporation to Announce Fourth Quarter and Year-End 2018 Financial Results on March 1, 2019

On February 26, 2019 Omeros Corporation (NASDAQ: OMER), reported that the company will issue its fourth quarter and year-end 2018 financial results for the period ended December 31, 2018, on Friday, March 1, 2019, before the market opens (Press release, Omeros, FEB 26, 2019, View Source [SID1234533687]). Omeros management will host a conference call and webcast that day at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss the financial results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call Details

To access the live conference call via phone, please dial (844) 831-4029 from the United States and Canada or (920) 663-6278 internationally. The participant passcode is 3544038. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available for one week following the call and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 3544038.

To access the live or subsequently archived webcast of the conference call on the internet, go to the company’s website at www.omeros.com and select "Events" under the Investors section of the website. To access the live webcast, please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.

Immatics announces Clinical Trial Collaboration in Immunotherapy for Solid Cancers

On February 26, 2019 Immatics reported a collaboration with Roche to evaluate the safety and efficacy of IMA101, Immatics’ investigational autologous cell therapy, in combination with atezolizumab (TECENTRIQ), in patients with solid cancers (Press release, immatics biotechnologies, FEB 26, 2019, View Source [SID1234554002]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

IMA101 is a personalized, multi-targeted investigational immunotherapy for the treatment of multiple advanced/ metastatic solid tumors. IMA101 is based on Immatics’ ACTolog approach, which follows the principle of expanding target-specific endogenous T-cells, a technique pioneered by Cassian Yee, M.D., Professor of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer Center.

The combination trial will evaluate potential synergistic effects generated by using the investigational immunotherapies together, as atezolizumab may enhance IMA101’s ability to kill cancer cells by blocking inhibitory immune checkpoints.

The combination clinical trial which is expected to begin later this year under an amendment to the ACTolog IMA101-101 study protocol (Clinicaltrials.gov: NCT02876510) will be conducted at MD Anderson, led by Apostolia Tsimberidou, M.D., Ph.D., Professor of Department of Investigational Cancer Therapeutics at MD Anderson.

Stephen Eck, M.D., Ph.D., Chief Medical Officer (CMO) at Immatics US, Inc., said: "Our innovative ACTolog process allows us to utilize a patient’s own T cells to generate a targeted approach for treating solid tumors with increased safety and efficacy potential. We are extremely pleased that, in collaboration with our long-term partner, we are now combining this promising personalized cell therapy with atezolizumab."

About ACTolog T-cell therapy

The ACTolog IMA101 phase 1 clinical trial is led by Prof. Apostolia Tsimberidou, Professor at the Department of Investigational Cancer Therapeutics at the University of Texas MD Anderson Cancer Center and co-funded by the Cancer Prevention and Research Institute of Texas (CPRIT). The ACTolog concept is based on the principle of endogenous T-cell therapy pioneered by Professor Cassian Yee, M.D. Unlike tumor-infiltrating lymphocytes, ACTolog T-cell products are generated from peripheral blood cells with defined target selectivity. Utilizing its proprietary antigen discovery platform XPRESIDENT, Immatics has created a warehouse of eight cancer targets. From this warehouse, the most suitable targets for each patient’s tumor are identified by analyzing the tumor biomarkers. Up to four personalized T-cell products are then activated and manufactured for each patient by isolation and enrichment of the patient’s endogenous T cells in vitro. Billions of such activated and specific T cells are then re-infused into the cancer patient to attack the tumor. The ACTolog T-cell products are manufactured at The Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory in collaboration with The University of Texas Health Science Center in Houston (UTHealth).

Alkermes Initiates Clinical Study of ALKS 4230 Administered Subcutaneously in Patients With Advanced Solid Tumors

On February 26, 2019 Alkermes plc (Nasdaq: ALKS) reported the initiation of ARTISTRY-2, a new clinical study of ALKS 4230 administered subcutaneously as monotherapy and in combination with the PD-1 inhibitor KEYTRUDA (pembrolizumab) in patients with advanced solid tumors (Press release, Alkermes, FEB 26, 2019, View Source;p=irol-newsArticle&ID=2388952 [SID1234533688]). The study will explore the safety, tolerability and efficacy of ALKS 4230 administered subcutaneously and assess once-weekly and once-every-three-week dosing schedules. ALKS 4230 is a novel, engineered fusion protein designed to selectively activate tumor-killing immune cells while avoiding the expansion of immunosuppressive cells by preferentially binding to the intermediate-affinity interleukin-2 (IL-2) receptor complex. Pembrolizumab is an anti-PD-1 therapy that works by increasing the ability of the body’s immune system to help detect and fight tumor cells.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ARTISTRY-2, a phase 1/2 study, will be conducted in two stages: dose-escalation followed by dose-expansion. The dose-escalation stage is designed to evaluate the safety and tolerability of ascending doses of ALKS 4230 administered subcutaneously once-weekly and once-every-three-weeks as both lead-in monotherapy and in combination with pembrolizumab. Following identification of the optimal dose and recommended dosing schedule, the dose-expansion stage of the study will evaluate ALKS 4230 administered subcutaneously in combination with pembrolizumab in patients with advanced solid tumors. The dose-expansion stage will evaluate overall response rate, duration of response, non-progression rate at specific time points and overall survival.

"The initiation of our clinical subcutaneous dosing study represents an important milestone for the ALKS 4230 program as we explore new regimens that may offer patients a more convenient alternative to daily IV dosing that is complementary to checkpoint inhibitor regimens," said Craig Hopkinson, M.D., Chief Medical Officer and Senior Vice President of Medicines Development and Medical Affairs at Alkermes. "Based on the emerging profile of ALKS 4230, we’ve rapidly expanded our clinical development program in recent months to evaluate combination therapy, potential efficacy in new tumor types and dosing optionality. The expansion of this program reflects our belief in the significant potential of ALKS 4230 and our recognition of the urgent and persistent need that exists for patients with cancer."

Data presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 33rd Annual Meeting demonstrated that subcutaneous administration of ALKS 4230 in non-clinical models achieved similar total systemic exposure of ALKS 4230 compared to intravenous (IV) administration, yet with less frequent dosing and a lower Cmax, leading to similar expansion of total CD8+ T cell and natural killer (NK) cell populations. These data support further clinical evaluation of subcutaneous administration of ALKS 4230 as an alternative to IV dosing.

About ALKS 4230
ALKS 4230 is a novel, engineered fusion protein designed to selectively activate tumor-killing immune cells while avoiding the expansion of immunosuppressive cells by preferentially binding to the intermediate-affinity interleukin-2 (IL-2) receptor complex. The selectivity of ALKS 4230 is designed to leverage the proven anti-tumor effects of existing IL-2 therapy while mitigating certain limitations.

About the ARTISTRY Clinical Program
ARTISTRY is an Alkermes-sponsored clinical program evaluating ALKS 4230 in patients with advanced solid tumors. ARTISTRY-1 is an ongoing phase 1 study in which ALKS 4230 is administered as an intravenous infusion daily for five consecutive days. ARTISTRY-1 has three distinct stages: an ongoing monotherapy dose-escalation stage, a planned monotherapy dose-expansion stage and an ongoing combination therapy stage with pembrolizumab. ARTISTRY-2 is the second clinical study to initiate in the ARTISTRY clinical development program for ALKS 4230.